NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The company announced the move on May 18, 2026, in a press release detailed at https://ibn.fm/Z8Etj.
The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants will carry an exercise price of $1.75 per share and a three-year term. Closing is expected on or about May 18, 2026, subject to customary conditions.
This capital infusion comes at a critical time for NanoViricides as it advances its clinical-stage antiviral drug NV-387. The drug has been granted an “Orphan Drug Designation” (ODD) by the U.S. FDA Office of Orphan Products Development (OOPD), which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is designed as a broad-spectrum antiviral based on host-mimetic nanomedicine technology, which the company believes viruses and their variants cannot escape.
The implications of this offering are significant for the company’s pipeline. NV-387 has shown effectiveness in lethal animal infection models for a range of viruses, including Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles. NanoViricides positions the drug as a potential first-line treatment for patients presenting with respiratory viral illnesses. The additional funding will likely support ongoing clinical trials and regulatory processes, bringing the drug closer to potential approval.
For investors, the offering provides an opportunity to participate in the company’s growth, though it also dilutes existing shares. The company’s news and updates are available at https://ibn.fm/NNVC. NanoViricides continues to operate as a clinical-stage company with a focus on developing antivirals that address unmet medical needs, particularly in the realm of emerging viral threats.
The offering underscores the ongoing interest in nanomedicine-based approaches to antiviral therapy. As the world grapples with viral outbreaks, the development of broad-spectrum treatments like NV-387 could have far-reaching public health implications.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides Prices $2 Million Registered Direct Offering.